rifampin has been researched along with Enteritis* in 8 studies
2 review(s) available for rifampin and Enteritis
Article | Year |
---|---|
[Diagnosis and antibiotic treatment of reactive arthritis].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Arthritis, Reactive; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Ciprofloxacin; Clinical Trials as Topic; Diagnosis, Differential; DNA, Bacterial; Drug Therapy, Combination; Enteritis; Female; Humans; Male; Models, Theoretical; Polymerase Chain Reaction; Rifampin; Salmonella; Salmonella Infections; Sensitivity and Specificity; Tetracyclines; Time Factors; Urethritis; Uterine Cervicitis; Yersinia; Yersinia Infections | 2002 |
[Actual problems in clinical chemotherapy].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Cephalosporins; Endocarditis, Bacterial; Enteritis; Gentamicins; Humans; Infections; Lincomycin; Meningitis; Penicillins; Rifampin; Sepsis; Staphylococcal Infections; Streptococcal Infections; Sulfonamides; Urinary Tract Infections; Vancomycin | 1967 |
6 other study(ies) available for rifampin and Enteritis
Article | Year |
---|---|
Lawsonia intracellularis-associated proliferative enteritis in weanling foals in the Netherlands.
Equine proliferative enteropathy (EPE) is an emerging infectious enteric disease caused by the obligate intracellular gram-negative bacterium Lawsonia intracellularis. EPE was tentatively diagnosed in six weanling foals, aged between 5 and 7 months. Clinical signs included depression, anorexia, ventral oedema, and weight loss. Plasma biochemistry consistently revealed severe hypoproteinaemia. The ante-mortem diagnosis of EPE was based on clinical signs, hypoproteinaemia (6/6), the detection of moderate-to-high titres of L. intracellularis antibody (6/6), and severe thickening of the small intestinal wall on ultrasonography (2/2), or L. intracellularis detected in faeces by PCR (I/2). The first foal died despite treatment and at post-mortem examination the tentative diagnosis was EPE. Three foals from the same farm, which showed similar clinical symptoms were treated with azithromycin and rifampicin; two survived. Post-mortem examination of the foal that died confirmed the tentative clinical diagnosis of EPE on the basis of the lesions found and the detection of L. intracellularis--DNA in the ileum and jejunum. The fifth foal died despite intensive treatment and the post-mortem examination revealed lymphohistiocytic enteritis, typhlitis, and widespread thrombosis in several organs. The sixth foal recovered completely after treatment. This report confirms the presence of clinical L. intracellularis infection in weanling foals in the Netherlands and shows the difficulty in reaching a definitive ante-mortem diagnosis. Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Communicable Diseases, Emerging; Desulfovibrionaceae Infections; Disease Outbreaks; Enteritis; Female; Horse Diseases; Horses; Lawsonia Bacteria; Male; Netherlands; Rifampin; Weaning | 2011 |
Equine proliferative enteropathy: a cause of weight loss, colic, diarrhoea and hypoproteinaemia in foals on three breeding farms in Canada.
Proliferative enteropathy (PE) is a transmissible enteric disease caused by Lawsonia intracellularis. An outbreak of equine PE was diagnosed in foals from 3 breeding farms. Most foals had been weaned prior to the appearance of clinical signs, which included depression, rapid and marked weight loss, subcutaneous oedema, diarrhoea and colic. Poor body condition with a rough haircoat and a potbellied appearance were common findings in affected foals. Respiratory tract infection, dermatitis and intestinal parasitism were also found in some foals. Haematological and plasma biochemical abnormalities included hypoproteinaemia, transient leucocytosis, anaemia and increased serum creatinine kinase concentration. Postmortem diagnosis of PE was confirmed on 4 foals based on the presence of characteristic intracellular bacteria within the apical cytoplasm of proliferating crypt epithelial cells of the intestinal mucosa, using silver stains, and by results of PCR analysis and immunohistochemistry. Antemortem diagnosis of equine PE was based on the clinical signs, hypoproteinaemia and the exclusion of common enteric infections. Faecal PCR analysis was positive for the presence of L. intracellularis in 6 of 18 foals tested while the serum of all 7 foals with PE serologically evaluated had antibodies against L. intracellularis. Most foals were treated with erythromycin estolate alone or combined with rifampin for a minimum of 21 days. Additional symptomatic treatments were administered when indicated. All but one foal treated with erythromycin survived the infection. This study indicates that equine PE should be included in the differential diagnosis of outbreaks of rapid weight loss, diarrhoea, colic and hypoproteinaemia in weanling foals. Topics: Animal Husbandry; Animals; Canada; Colic; Diarrhea; Disease Outbreaks; Drug Therapy, Combination; Enteritis; Erythromycin Estolate; Gram-Negative Bacterial Infections; Horse Diseases; Horses; Hypoproteinemia; Lawsonia Bacteria; Rifampin; Weight Loss | 2000 |
Antibiotic and deoxycholate resistance in Campylobacter jejuni following freezing or heating.
The surviving populations of Campylobacter jejuni serotypes following freezing or heat were found to be more sensitive to rifampicin and sodium deoxycholate on subsequent culture. Thus while control cultures had an IC50 of greater than 20 micrograms/ml rifampicin those of injured cells were less than 5 micrograms/ml. Treatment with EDTA caused almost identical changes in resistance suggesting that the altered resistance pattern of injured cells was due to loss of the barrier properties of the bacterial outer membrane. Topics: Anti-Bacterial Agents; Campylobacter; Campylobacter Infections; Deoxycholic Acid; Drug Resistance, Microbial; Edetic Acid; Enteritis; Freezing; Hot Temperature; Humans; Rifampin | 1985 |
[Elimination of multidrug resistance in E. coli in calves in vivo with rimactan].
An experiment was carried out for eliminating the multimedicinal resistance markers of E. coli, populating the intestinal tract of calves, in vivo with rimactan introduced per os, and rationed 10 mg/kg of live weight, once during a period of 8 days. The highest percentage and the longest elimination were observed for the neomycin, the novobiocin and the chlornitromycin resistance markers. The elimination was weaker for the erythromycin, the streptomycin and the kanamycin markers and the weakest was for the penicillin and tetracycline markers. There appeared a difference in the elimination of the resistance markers with the different calves, especially for the markers with a low degree of elimination, depending on the individual peculiarities of the calves. Riphamycin proved to be an eliminating means for the resistance markers of E coli in vivo of calves suffering from enteritis. Alongside with the elimination of the resistance markers, due to the treatment of calves with rimactan, an almost complete recovery was achieved. Rimactan is a reliable means for fighting enteric illnesses with calves, caused by enteropathogenic E. coli. Topics: Animals; Cattle; Cattle Diseases; Drug Evaluation; Drug Resistance, Microbial; Enteritis; Escherichia coli; Escherichia coli Infections; Genetic Markers; Microbial Sensitivity Tests; Rifampin | 1980 |
[Rifampicin in pediatric practice].
Topics: Abscess; Bronchopneumonia; Empyema; Enteritis; Humans; Pharyngitis; Pneumonia; Respiratory Tract Infections; Rhinitis; Rifampin; Skin Diseases | 1969 |
[Rifomycin in pediatric care].
Topics: Child, Preschool; Enteritis; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature, Diseases; Pediatrics; Respiratory Tract Diseases; Rifampin; Urinary Tract Infections | 1969 |